Download PDFPDF
Original article
Therapeutic potential of valproic acid for retinitis pigmentosa
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

  • Published on:
    Author Response Re: "Need to further investigate the efficacy of valproic acid therapy in retinal degenerative disorders" letter
    • Radouil Tzekov
    • Other Contributors:
      • , Christine Clemson, Mark Krebs, Jenna Checchi, Shalesh Kaushal

    Dear Editor,

    We appreciate the interest of Dr. Kahn and Dr. Philip [1] in our paper describing pilot results from a retrospective study in patients with retinitis pigmentosa (RP) treated with valproic acid (VPA) [2], and we would like to comment on the points raised by them.

    Length of treatment. As mentioned in our recent reply to another letter regarding the same article [3], the length of treatment...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Need to further investigate the efficacy of valproic acid therapy in retinal degenerative disorders
    • Sujoy Khan, Consultant Immunologist, Frimley Park Hospital NHS Foundation Trust, Frimley, Surrey, GU16 7UJ, UK
    • Other Contributors:
      • Swetha Philip, Consultant Ophthalmologist, Christian Medical College & Hospital, Vellore, India

    Dear Editor,

    We have a few concerns on the report by Clemson CM et al on the efficacy of valproic acid (VPA) in 7 patients with retinitis pigmentosa (RP) [1]. Was the time period of 6 months for using VPA the maximum time that was allowed by the institutional review boards? The degree to which the retina was affected by RP was not mentioned in each case (either in the form of photographic evidence or by electro...

    Show More
    Conflict of Interest:
    None declared.